Abstract
Chronic inflammation has been implicated in the pathogenesis of many common chronic
diseases, including cancer. C-reactive protein (CRP) concentration is a non-specific
serum marker of inflammation, and higher levels have been observed among individuals
who go on to develop cardiovascular disease. Nested case-control studies were conducted
within the CLUE II study, a community-based cohort, to examine the association between
CRP concentrations and subsequent development of colorectal or prostate cancer. CRP
concentrations were higher among individuals who went on to develop colon cancer,
but not rectal or prostate cancer, compared with controls. The association between
CRP concentrations and development of colon cancer is consistent with other evidence
suggesting a role of inflammation and cancer. Preventive interventions that decrease
systemic chronic inflammation have the potential to reduce certain types of cancer
as well as cardiovascular disease. However, the potential benefits of anti-inflammatory
chemopreventive agents must be weighed against their adverse effects before widespread
use is recommended.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical efficacy of an automated high-sensitivity C-reactive protein assay.Clin Chem. 1999; 45: 2136-2141
- Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.N Engl J Med. 1997; 336 ([Erratum: N Engl J Med 1997;337:356): 973-979
- C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.N Engl J Med. 2000; 342: 836-843
- C-reactive protein and the risk of incident colorectal cancer.JAMA. 2004; 291: 585-590
- No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostrate cancer.Prostate. 2004; 59: 393-400
Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. C-reactive protein (CRP) and colorectal cancer incidence in a cohort of male smokers.Proceedings Frontiers in Cancer Prevention, Baltimore, MD, October 2005.
- Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort.Cancer Epidemiol Biomarkers Prev. 2005; 14: 2413-2418
Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality, an individual participant meta-analysis. JAMA 2005;294:1799–809.
- C-reactive protein levels are not associated with increased risk for colorectal cancer in women.Ann Intern Med. 2005; 142: 425-432
- Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC study.J Epidemiol. 2005; : S185-S189
- Aspirin use and risk of fatal cancer.Cancer Res. 1993; 53: 1322-1327
- Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.JAMA. 2005; 294: 914-923
- A randomized trial of aspirin to prevent colorectal adenomas.N Engl J Med. 2003; 348: 891-899
- A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.N Engl J Med. 2003; 348: 883-890
- Aspirin use and colorectal cancer: post-trial follow-up data from the physicians’ health study.Ann Intern Med. 1998; 128: 713-720
- Low-dose aspirin in the primary prevention of cancer. The women’s health study: a randomized controlled trial.JAMA. 2005; 294: 47-55
- COX-2: a molecular target for colorectal cancer prevention.J Clin Oncol. 2005; 23: 2840-2855
- COX-2 inhibitors – a lesson in unexpected problems.N Engl J Med. 2005; 352: 1131-1132
- COX-2 inhibitors-lessons in drug safety.N Engl J Med. 2005; 352: 1133-1135
- Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.N Engl J Med. 2005; 352: 1071-1080
- Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.N Engl J Med. 2005; 352: 1092-1102
- Intermediate markers as surrogate endpoints in cancer research.Hematol Oncol Clin North Am. 2000; 14: 887-905
- Natural history of colorectal cancer.Am J Med. 1999; 106: 3S-6S
- Colorectal polyps and their relationship to cancer.Gastroenterol Clin North Am. 1997; 26: 1-17
Colorectal Cancer Fact Sheet. Available from: http://www.cdc.gov/colorectalcancer/what_cdc_is_doing/about_cdc_program.htm.
- Tamoxfen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst. 1998; 90: 1371-1388
- Using numerical results from systematic reviews in clinical practice.Ann Intern Med. 1997; 126: 712-720
Aspirin for the primary prevention of cardiovascular events: summary of the evidence. Article originally in Annals of Internal Medicine 2002. Rockville, MD: Agency for Healthcare Research and Quality. Available from: http://www.ahrq.gov/clinic/ 3rduspstf/aspirin/aspsum1.htm.
- Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.Cancer. 2005; 103: 1147-1153
Article info
Publication history
Accepted:
January 11,
2006
Received:
January 11,
2006
Identification
Copyright
© 2006 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
